Form 4: Ng George K reports acquisition/exercise transactions in HURA

Rhea-AI Filing Summary

Ng George K reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

10500 UNIVERSITY CENTER DRIVE, SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$1.29	02/12/2026(1)		A		156,240		(1)	02/12/2036	Common Stock	156,240	$0	156,240	D
Options (Right to Buy)	$4.11							(2)	01/02/2035	Common Stock	51,275		51,275	D

Explanation of Responses:

1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

	/s/ Dan Dearborn as Power of Attorney for George Ng	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TuHURA Biosciences (HURA) disclose about George Ng on this Form 4?

TuHURA Biosciences reported that director George K. Ng received an annual grant of 156,240 stock options on February 12, 2026. The options were issued under the 2024 Equity Incentive Plan and give him the right to buy TuHURA common stock at a fixed exercise price.

How many TuHURA (HURA) stock options did George Ng receive and at what price?

George Ng received 156,240 options to purchase TuHURA common stock at an exercise price of $1.29 per share. These options are part of an annual grant and were reported as acquired at a price of $0.00 per option as a compensatory award.

What is the vesting schedule for George Ng’s new TuHURA (HURA) stock options?

The new 156,240 TuHURA options vest in three equal installments. One-third becomes exercisable on each of the first, second, and third anniversaries of February 12, 2026, creating a three-year vesting period tied to continued service or other plan conditions.

What prior TuHURA (HURA) option grant to George Ng is referenced in the filing?

The filing notes a prior annual option grant to George Ng from January 2, 2025 under the same 2024 Equity Incentive Plan. That earlier award covers 51,275 options with a $4.11 exercise price, vesting one-third on each of the first three anniversaries of January 2, 2025.

Is George Ng’s ownership in TuHURA (HURA) direct or through another entity?

The Form 4 shows George Ng’s derivative holdings as directly owned, marked with an ownership code of “D” for direct. No footnotes indicate that these options are held through a separate trust, LLC, or other indirect entity for this particular reporting.

What role does George Ng hold at TuHURA Biosciences (HURA)?

George Ng is identified as a director of TuHURA Biosciences. The Form 4’s relationship section checks the “Director” box and does not mark him as a ten percent owner or officer, indicating his reportable transactions relate to his board position.